Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
from Economic Times https://ift.tt/NKGOwbZ
from Economic Times https://ift.tt/NKGOwbZ
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?
![Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?]()
Reviewed by News Today
on
July 06, 2024
Rating:
No comments: